Journey Advisory Group LLC Sells 1,271 Shares of Johnson & Johnson (NYSE:JNJ)

Journey Advisory Group LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,250 shares of the company’s stock after selling 1,271 shares during the period. Journey Advisory Group LLC’s holdings in Johnson & Johnson were worth $4,421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Foster & Motley Inc. raised its position in Johnson & Johnson by 2.8% during the second quarter. Foster & Motley Inc. now owns 47,731 shares of the company’s stock valued at $6,976,000 after purchasing an additional 1,298 shares during the period. Meridian Wealth Advisors LLC raised its position in Johnson & Johnson by 1.6% during the second quarter. Meridian Wealth Advisors LLC now owns 14,468 shares of the company’s stock valued at $2,115,000 after purchasing an additional 234 shares during the period. Impact Partnership Wealth LLC raised its position in Johnson & Johnson by 428.1% during the second quarter. Impact Partnership Wealth LLC now owns 7,034 shares of the company’s stock valued at $1,028,000 after purchasing an additional 5,702 shares during the period. Deseret Mutual Benefit Administrators raised its position in Johnson & Johnson by 2.5% during the second quarter. Deseret Mutual Benefit Administrators now owns 12,754 shares of the company’s stock valued at $1,864,000 after purchasing an additional 307 shares during the period. Finally, Range Financial Group LLC raised its position in Johnson & Johnson by 3.1% during the second quarter. Range Financial Group LLC now owns 12,148 shares of the company’s stock valued at $1,776,000 after purchasing an additional 361 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE:JNJ opened at $164.41 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock has a market cap of $395.68 billion, a P/E ratio of 10.25, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52. The business’s 50 day moving average is $157.57 and its 200 day moving average is $153.83. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.80 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 30th. Finally, TD Securities reduced their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.